BCL2 and cancer: Additionally, the regulation of the PI3K/AKT/mTOR signaling pathway, reduction in the expression levels of Bcl-2, mTOR, and P70S6k, as well as the overexpression of pro-apoptotic proteins like Bax, demonstrate the multi-targeted mechanism of securinine in cancer therapy (33, 34).